THERAPEUTIC TARGETING OF MDS & AML STEM CELLS WITH AN ANTISENSE INHIBITOR OF STAT3

被引：0
|
作者：
Shastri, A. [1 ]
Teixeira, M. [2 ]
Bhattacharya, S. [3 ]
Ramachandra, N. [3 ]
Lopez, R. [1 ]
Ravipati, G. [1 ]
Bhagat, T. [3 ]
Choudhary, G. [3 ]
Bartenstein, M. [3 ]
Gordon-Mitchell, S. [3 ]
Pradhan, K. [4 ]
Pellagatti, A. [5 ]
Boultwood, J. [6 ]
Kim, Y. [7 ]
Woessner, R. [8 ]
Will, B. [2 ]
Steidl, U. [2 ]
Verma, A. [1 ]
机构：
[1] Albert Einstein Coll Med, Hematooncol, New York, NY USA
[2] Albert Einstein Coll Med, Cell Biol, New York, NY USA
[3] Albert Einstein Coll Med, Mol Biol, New York, NY USA
[4] Albert Einstein Coll Med, Biostat, New York, NY USA
[5] Univ Oxford, Cell & Mol Biol, Oxford, England
[6] Univ Oxford, Mol Hematol, Oxford, England
[7] Ionis Biotech, San Diego, CA USA
[8] Astrazeneca, Boston, MA USA
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30128-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [31] Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor
    Miyoshi, Ken
    Takaishi, Mikiro
    Nakajima, Kimiko
    Ikeda, Mitsunori
    Kanda, Takashi
    Tarutani, Masahito
    Iiyama, Tatsuo
    Asao, Naoki
    DiGiovanni, John
    Sano, Shigetoshi
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (01) : 108 - 117
  • [32] STAT3, stem cells, cancer stem cells and p63
    Galoczova, Michaela
    Coates, Philip
    Vojtesek, Borivoj
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2018, 23
  • [33] Therapeutic Targeting of Stat3 Pathways in Autoimmune Inflammatory Disease of the CNS
    Yu, C.
    Lee, Y.
    Mahdi, R.
    Burton, J.
    Egwuagu, C. E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [34] A NICHE-DIRECTED THERAPEUTIC APPROACH TARGETING MDS AND AML
    Mosialou, Ioanna
    Luo, Na
    Galan-Diez, Marta
    Ali, Abdhullah
    Raza, Azra
    Kousteni, Stavroula
    EXPERIMENTAL HEMATOLOGY, 2021, 100 : S38 - S38
  • [35] STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma
    Oi, Toru
    Asanuma, Kunihiro
    Matsumine, Akihiko
    Matsubara, Takao
    Nakamura, Tomoki
    Iino, Takahiro
    Asanuma, Yumiko
    Goto, Mikinobu
    Okuno, Kazuma
    Kakimoto, Takuya
    Yada, Yuki
    Sudo, Akihiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) : 2275 - 2284
  • [36] CD99 Is a Diagnostic and Therapeutic Target on Disease Stem Cells in MDS and AML
    Chung, S. S.
    Pang, W. W.
    Devlin, S.
    Klimek, V. M.
    Melnick, A.
    Park, C. Y.
    MODERN PATHOLOGY, 2014, 27 : 343A - 343A
  • [37] STAT3 inhibitor WP1066 as a novel therapeutic for medulloblastoma
    Metrock, Laura K.
    Liu, Jingbo
    Yuan, Liangping
    Zhang, Hongying
    Dey, Abhinav
    MacDonald, Tobey
    CANCER RESEARCH, 2016, 76
  • [38] CD99 Is a Diagnostic and Therapeutic Target on Disease Stem Cells in MDS and AML
    Chung, S. S.
    Pang, W. W.
    Devlin, S.
    Klimek, V. M.
    Melnick, A.
    Park, C. Y.
    LABORATORY INVESTIGATION, 2014, 94 : 343A - 343A
  • [39] Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses
    Brown, Jennifer R.
    Walker, Sarah R.
    Heppler, Lisa N.
    Tyekucheva, Svitlana
    Nelson, Erik A.
    Klitgaard, Josephine
    Nicolais, Maria
    Kroll, Yasmin
    Xiang, Michael
    Yeh, Jennifer E.
    Chaudhury, Mousumi
    Giaccone, Zachary T.
    Fernandes, Stacey M.
    Jacobsen, Eric D.
    Fisher, David C.
    Freedman, Arnold S.
    Davids, Matthew S.
    Supko, Jeffrey G.
    Wu, Catherine
    Frank, David A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : E95 - E98
  • [40] Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
    Wei, Jia
    Ma, Ling
    Li, Chenglong
    Pierson, Christopher R.
    Finlay, Jonathan L.
    Lin, Jiayuh
    CURRENT CANCER DRUG TARGETS, 2019, 19 (07) : 571 - 582
12345